Skip to main content

Advertisement

SpringerLink
Log in

Botulinum Toxin Treatment of Movement Disorders

  • Movement Disorders (A Videnovich, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Botulinum neurotoxins (BoNTs) are now among the most widely used therapeutic agents in clinical medicine with indications applied to the fields of movement disorders, pain disorders, and autonomic dysfunction. In this literature review, the efficacy and utility of BoNTs in the field of movement disorders are assessed using the criteria of the Guideline Development Subcommittee of the American Academy of Neurology. The literature supports a level A efficacy (established) for BoNT therapy in cervical dystonia and a level B efficacy (probably effective) for blepharospasm, hemifacial spasm, laryngeal dystonia (spasmodic dysphonia), task-specific dystonias, essential tremor, and Parkinson rest tremor. It is the view of movement disorder experts, however, that despite the level B efficacy, BoNTs should be considered treatment of first choice for blepharospasm, hemifacial spasm, laryngeal, and task-specific dystonias. The emerging data on motor and vocal tics of Tourette syndrome and oromandibular dystonias are encouraging but the current level of efficacy is U (undetermined) due to lack of published high-quality studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rothman AE. The protein machinery of vesicle budding and fusion. Protein Sci. 1996;5:185–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gronseth G, French J. Invited Article: Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology. 2008;71:639–1643.

    Article  Google Scholar 

  3. ••Karp BI, Alter KE. Botulinum treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol 2016; 84–91. This is a very nice and focused review of botulinum toxin treatment in blepharospasm, facial dystonias and hemifacial spasm.

  4. Peckham EL, Lopez G, Shamim EA et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol 2011; 18:282–286

  5. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm: a randomized trial. Mov Disord. 2011;26:1521–8.

    Article  PubMed  Google Scholar 

  6. Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord. 1996;11:27–31.

    Article  CAS  PubMed  Google Scholar 

  7. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197–9.

    Article  CAS  PubMed  Google Scholar 

  8. Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14(8):407–14.

    Article  PubMed  Google Scholar 

  9. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118:233–9.

    Article  CAS  PubMed  Google Scholar 

  10. Saad J, Gourdeau A. A direct comparison of onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a splitface technique. J Neuroophthalmol. 2014;34:233–6.

    Article  PubMed  Google Scholar 

  11. •• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary. Botulinum toxins for treatment of blepharospasm, cervical dystonia adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:1818–26. This paper defines the latest guidelines of American Academy of Neurology regarding the efficacy of Botulinum toxins in treatment of Movement Disorders.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sinclair CF, Gurey LE, Blitzer A. Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope. 2013;123:3078–83.

    Article  CAS  PubMed  Google Scholar 

  13. Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol. 2013;156:173–7. e172

    Article  CAS  PubMed  Google Scholar 

  14. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon: Off J Int Soc Toxinol. 2014;90:344–8.

    Article  CAS  Google Scholar 

  15. Biuk D, Karin AA, Matic S, Barac J, Benasic T, Stiglmayer N. Quality of life in patients with blepharospasm. Coll Antropol. 2013;37:29–33.

    PubMed  Google Scholar 

  16. Streitova H, Bares M. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg. 2014;114:285–91.

    Article  PubMed  Google Scholar 

  17. Colosim C, Bolognia M, Lambtri S et al. Comparative study of primary and secondary hemifacial spasm. 2006;63:441–444

  18. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627–30. https://doi.org/10.1212/WNL.42.3.627131.

    Article  CAS  PubMed  Google Scholar 

  19. Poungvarin N, Viriyavejakul A, Komoltri C. Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm. Parkinsonism Relat Disord. 1995;1:85–8.

    Article  CAS  PubMed  Google Scholar 

  20. Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord. 1997;12:1013–8.

    Article  CAS  PubMed  Google Scholar 

  21. Rieder CR, Schestatsky P, Socal MP et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm

  22. Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type A botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol. 2010;33:27–31.

    CAS  PubMed  Google Scholar 

  23. • Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114. Provides Evidence-based review and assessment of a group Movement disorders experts on n neurotoxin treatment for involuntary movements.

    Article  CAS  PubMed  Google Scholar 

  24. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254–61.

    Article  PubMed  Google Scholar 

  25. Batla A, Goyal C, Shukla G, Goyal V, Srivastava A, Behari M. Hemifacial spasm: clinical characteristics of 321 Indian patients. J Neurol. 2012;259:1561–5.

    Article  PubMed  Google Scholar 

  26. Batisti JP, Kleinfelder AD, Galli NB, et al. Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated. Arq Neuropsiquiatr. 2017;75:87–91.

    Article  PubMed  Google Scholar 

  27. Gutmann L, Gutmann L. Myokymia and neuromyotonia. J Neurol. 2004;251:138–42.

    Article  PubMed  Google Scholar 

  28. Andermann F, Cosgrove JBR, Lloyd-Smith DL, Gloor P, McNaughton FL. Facial myokymia in multiple sclerosis. Brain. 1961;84:31–44.

    Article  Google Scholar 

  29. Sedano MJ, Trejo JM, Macarrón JL, Polo JM, Berciano J, Calleja J. Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol. 2000;43:137–40.

    Article  CAS  PubMed  Google Scholar 

  30. Habek M, Adamec I, Gabelić T, Brinar VV. Treatment of facial myokymia in multiple sclerosis with botulinum toxin. Acta Neurol Belg. 2012;112:423–4.

    Article  PubMed  Google Scholar 

  31. Rogatko CP, Glass EN, Kent M, et al. Use of botulinum toxin type A for the treatment of radiation therapy-induced myokymia and neuromyotonia in a dog. J Am Vet Med Assoc. 2016 Mar 1;248:532–7.

    Article  CAS  PubMed  Google Scholar 

  32. Inoue N, Nagahiro S, Kaji R, Goto S. Long-term suppression of Meige syndrome after pallidal stimulation: a 10-year follow-up study. Mov Disord. 2010;25:1756–8.

    Article  PubMed  Google Scholar 

  33. Rosales RL, Ng AR, Santos MM. The broadening application of chemodenervation in X-linked dystonia-Parkinsonism: an open-label experience with botulinum toxin—a (Dysport) injections for oromandibular, lingual and truncal-axial dystonias. Int J Neurosci. 2011;121(Suppl 1):44–56.

    Article  CAS  PubMed  Google Scholar 

  34. Nastasi L, Mostile G, Nicolleti A, et al. Effect of botulinum toxin treatment on quality of life in patients with isolated LD and OMD affecting the tongue. J Neurol. 2016;263:1702–8.

    Article  CAS  PubMed  Google Scholar 

  35. Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16:438–41.

    Article  PubMed  Google Scholar 

  36. Contarino MF, Van Den Doo J, Balash Y, et al. Clinical practice: evidenced based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol. 2017;8:35. https://doi.org/10.3389/fneur.2017.00035. eCollection

    Article  PubMed  PubMed Central  Google Scholar 

  37. Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27:1789–96.

    Article  PubMed  Google Scholar 

  38. Jankovic J, Adler CH, Charles D. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015;349:84–93.

    Article  PubMed  Google Scholar 

  39. •• Charles PD, Adler CH, Stacy M, et al. Cervical dystonia pain: characteristics and treatment patterns from Cervical Dystonia Registry for observations of onabotulinum toxin A efficacy. J Neurol. 2014;26:1309–19. Provides data on demographics of cervical dystonia from a large cervical dystonia registry.

    Article  Google Scholar 

  40. Volkmann J, Mueller J, Deuschl G, Kuhn AA, Krauss JK, Poewe W, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol. 2014;13:875–84.

    Article  PubMed  Google Scholar 

  41. • Bledsoe IO, Comella CL. Botulinum toxin treatment of cervical dystonia. Semin Neurol. 2016;36:47–53. An updated review of botulinum toxin treatment in cervical dystonia.

    Article  PubMed  Google Scholar 

  42. Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35(5):208–14.

    Article  CAS  PubMed  Google Scholar 

  43. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64(1):13–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783–91.

    Article  PubMed  Google Scholar 

  45. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316–23.

    Article  PubMed  Google Scholar 

  46. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1–2):103–9.

    Article  CAS  PubMed  Google Scholar 

  47. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701–7.

    Article  CAS  PubMed  Google Scholar 

  48. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439–46.

    Article  CAS  PubMed  Google Scholar 

  49. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431–8.

    Article  CAS  PubMed  Google Scholar 

  50. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949–51.

    Article  CAS  PubMed  Google Scholar 

  51. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423–9.

    Article  CAS  PubMed  Google Scholar 

  52. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510–7.

    Article  PubMed  Google Scholar 

  53. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Charles PD, Manack Adams A, Davis T. Neck pain and cervical dystonia: treatment outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). Pain Pract. 2016; https://doi.org/10.1111/papr.12408.

  55. Kaji R, Shimizu H, Takase T, et al. A double blind comparative study to evaluate the efficacy and safety of NerBlock (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia. Brain Nerve. 2013;65:302–211.

    Google Scholar 

  56. Fernandez HH, Pappert EJ, Comella CL et al. Efficacy and Safety of incobotulinum toxinA in patients previously treated with botulinum toxin versus toxin naïve subjects with cervical dystonia. Tremor Other Heperkinet Mov.

  57. Ranoux D, Gury C, Fundarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:459–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Mordin M, Masaquel C, Abbott C, et al. Factors affecting the health related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxina (Dysport): results from a randomized, double blind, placebo controlled study. BMJ Open. 2014 Oct 16;4(10):e005150. https://doi.org/10.1136/bmjopen-2014-005150.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Brin MF, Comella CL, Jankovic J. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–60.

    Article  PubMed  Google Scholar 

  60. Allison SK, Odderson IR. Ultrasound and electromyography guidance for injection of longus colli with botulinum toxin for treatment of cervical dystonia. Ultrasound Q. 2016 Sep;32(3):302–6. https://doi.org/10.1097/RUQ.0000000000000226.

    Article  PubMed  Google Scholar 

  61. Alter K, Karp BI. Ultrasound, electromyography, electrical stimulation; techniques aiding more effective botulinum toxin therapy. Chapter 15. In: Jabbari, editor. Botulinum toxin treatment in clinical medicine. New York: Springer Publisher; 2018.

    Google Scholar 

  62. Payne bA, Tisch S, Cole I, et al. The clinical spectrum of laryngeal dystonia includes dystonic cough: observation of a large series. Mov Disord. 2014;29:729–35.

    Article  PubMed  Google Scholar 

  63. Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol. 2010 Jul;17(Suppl 1):28–30.

    Article  PubMed  Google Scholar 

  64. Kirke DN, Frucht SJ, Simonyan K. Alcohol responsiveness in laryngeal dystonia: a survey study. J Neurol. 2015 Jun;262:1548–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Salloway S, Stewart C, Israeli L, et al. Botulinum toxin for refractory tics. Mov Disord. 1996;11:746.

    Article  CAS  PubMed  Google Scholar 

  66. Rumbach AF, Blitzer A, Frucht SJ, et al. An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope. 2017;127:1402–7.

    Article  CAS  PubMed  Google Scholar 

  67. Troung DD, Rontal M, Rolnick M. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630–4.

    CAS  PubMed  Google Scholar 

  68. Blitzer A, Zalvan C, Gonzalez-Yanez O, et al. Botulinum toxin type A injections for the management of the hyperfunctional larynx. Chapter 20: 207–216. In: Brin, Hallett, Jankovic, editors. Scientific therapeutic aspects of botulinum toxin. New York: Lippincot Williams and Willkins; 2002.

    Google Scholar 

  69. Blitzer A. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg. 2005;133

  70. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994;9:347–9.

    Article  CAS  PubMed  Google Scholar 

  71. Marras C, Andrew D, Sime E, et al. Botulinum toxin for simple motor tics: a randomized, double blind, controlled clinical trial. Neurology. 2001;56:605–10.

    Article  CAS  PubMed  Google Scholar 

  72. Trimble MR, Whur R, Brooks G, et al. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord. 1998;13:617–8.

    Article  CAS  PubMed  Google Scholar 

  73. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13(Suppl 3):2–23.

    PubMed  Google Scholar 

  74. Espay AJ, Lang AE, Erro R, et al. Essential pitfalls in “essential tremor”. Mov Disord. 2017;32:325–31.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Zesiewicz TA, Shaw JD, Allison KG, et al. Update on treatment of essential tremor. Update on treatment of essential tremor. Curr Treat Options Neurol. 2013;15:410–23.

    Article  PubMed  Google Scholar 

  76. Bruno E, Nicolleti A, Quattrochi G, et al. Topiramate for essential tremor. Cochrane Database Syst Rev. 2017;4:CD009683. https://doi.org/10.1002/14651858.CD009683.pub2.

    PubMed  Google Scholar 

  77. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord : Off J Mov Disord Soc. 1996;11:250–6.

    Article  CAS  Google Scholar 

  78. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–8.

    Article  CAS  PubMed  Google Scholar 

  79. Lotia M, Jankovic J. Botulinum toxin for the treatment of tremor and tics. Semin Neurol. 2016;36:54–63. This article discusses the value of botulinum toxin therapy for tics and tremors based on evidenced data.

    Article  PubMed  Google Scholar 

  80. Rostami R, Chow C, Richardson, et al. Botulinum toxin treatment of essential tremor—a customized approach. AAN Poster S. 2016;27(002)

  81. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. Jul 1996;53(7):617–24.

    Article  CAS  PubMed  Google Scholar 

  82. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol. 1996;36(1):29–35.

    Article  CAS  PubMed  Google Scholar 

  83. Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson’s disease upper limb tremor management. The Canadian Journal of Neurological Sciences. J Can Sci Neurol. Sep 2013;40(5):663–9.

    Article  Google Scholar 

  84. Shivam OM, Machado D, Richardson, et al. IncobotulinumtoxinA in Parkinson disease tremor—a randomized double blind, placebo-controlled study with a customized injection approach. Mayo Clin Proc. 2017;92:1359–67.

    Article  Google Scholar 

  85. Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One. 2017;12(6):e0178670. https://doi.org/10.1371/journal.pone.0178670.eCollection.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Lungu C, Ahmad OF. Update on botulinum toxin therapy for focal and task specific dystonias. Semin Neurol. 2016;36:41–6.

    Article  PubMed  Google Scholar 

  87. Kruisdijk JJ, Koelman JH, Ongerboer de visser BW et al. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry (2007) 78:264–270. doi:https://doi.org/10.1136/jnnp.2005.083170129.

  88. Contarino MF, Kruisdijk JJ, Koster L, et al. Sensory integration in writer’s cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol. 2007;118:2195–206. https://doi.org/10.1016/j.clinph.2007.07.004130.

    Article  CAS  PubMed  Google Scholar 

  89. Tsui JK, Bhatt M, Calne S, et al. Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology. 1993;43:183–5. https://doi.org/10.1212/WNL.43.1_Part_1.183132.

    Article  CAS  PubMed  Google Scholar 

  90. Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995;10:466–71. https://doi.org/10.1002/mds.870100411.

    Article  CAS  PubMed  Google Scholar 

  91. Prio Richardson S, Altenmüller E, Alter K. Research priorities in limb and task-specific dystonias. Front Neurol. 2017;8:170. https://doi.org/10.3389/fneur.2017.00170. eCollection 2017

    Article  Google Scholar 

  92. Alter K, Simpson, D, Elovic, E. Botulinum neurotoxin for the treatment of idiopathic primary limb dystonia, in botulinum neurotoxin injection manual. In: Alter K, Wilson N, editors. Demos Medical: New York; 2015.

  93. Spillane JD, Nathan PW, Kelly RE et al. Painful legs, moving toes. Brain; 94:541–556

  94. Dressler D, Thompson PD, Gledhill RF, et al. The syndrome of painful legs moving toes. Mov Disord. 1994;9:13–21.

    Article  CAS  PubMed  Google Scholar 

  95. Eisa M, Singer C, Sengun C, et al. Treatment of painful limbs/moving extremities with botulinum toxin type A injections. Eur Neurol. 2008;60:104–6.

    Article  PubMed  Google Scholar 

  96. Polo KB, Jabbari B. Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord. 1994;9(2):233–5.

    Article  CAS  PubMed  Google Scholar 

  97. Lagueny A, Tison F, Burbaud P, et al. Stimulus-sensitive spinal segmental myoclonus Improved with injections of botulinum toxin type A. Mov Disord. 1999;14:182–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of California, Irvine, USA

    Yasaman Safarpour MD

  2. Division of Movement Disorders, Department of Neurology, Yale University School of Medicine, New Haven-CT, 31 Silver Pine Drive, Newport Coast, CA, 92657, USA

    Bahman Jabbari MD

Authors
  1. Yasaman Safarpour MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bahman Jabbari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bahman Jabbari MD.

Ethics declarations

Conflict of Interest

Yasaman Safarpour declares no conflict of interest.

Bahman Jabbari has received grants from Allergan, Inc. and Pharma.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Movement Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Safarpour, Y., Jabbari, B. Botulinum Toxin Treatment of Movement Disorders. Curr Treat Options Neurol 20, 4 (2018). https://doi.org/10.1007/s11940-018-0488-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-018-0488-3

Keywords

Search

Navigation